About Anixa Biosciences Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.anixa.com/
Frequently Asked Questions
What is the 52-week range for ANIX?
The 52-week high is $5.4566 and the 52-week low is $2.32.
What is the P/E ratio for ANIX?
The P/E ratio data is currently unavailable.
What is the dividend yield for ANIX?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -70.17%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -1090.48%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 8.97.
Analyst Recommendation Trends
Wall Street analyst consensus for ANIX over the last few months:
Latest ANIX News
Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the second patient has been treated in the fifth cohort of its ongoing Phase 1, dose-escalating, clinical trial (ClinicalTrials.gov NCT05316129) evaluating its novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer. The study is being conducted at Moffitt Cancer Center ("Moffitt").
Anixa Biosciences Announces Second Patient Has Been Treated In Fifth Cohort Of Its Ongoing Phase 1, Dose-Escalating, Clinical Trial Evaluating FSHR-Targeted CAR-T Therapy For Recurrent Ovarian Cancer
The study is being conducted at Moffitt Cancer Center ("Moffitt"). The Phase 1 study is evaluating a novel CAR-T therapy targeting follicle stimulating hormone receptor (FSHR), which is expressed on ovarian
HC Wainwright & Co. Maintains Buy on Anixa Biosciences, Lowers Price Target to $6
HC Wainwright & Co. analyst Yi Chen maintains Anixa Biosciences (NASDAQ:ANIX) with a Buy and lowers the price target from $7 to $6.
Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that IP Australia has issued Patent Number 2020221280 related to Anixa's breast cancer vaccine technology, exclusively licensed from Cleveland Clinic. This composition-of-matter patent protects the Company's novel approach to breast cancer prevention and treatment in Australia through 2040, addressing a disease for which no preventive vacci
IP Australia Grants Patent To Anixa Biosciences’ Breast Cancer Vaccine Technology, Exclusively Licensed From Cleveland Clinic
Composition of matter patent secures exclusive protection for Anixa's breast cancer vaccine in Australia through 2040, expanding the Company's growing global IP estateContinues expansion of global intellectual
Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the appointment of Carmen Guerra, M.D., M.S.C.E., F.A.C.P., to its Cancer Business Advisory Board.
Anixa Biosciences and Nexalin Technology Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
ORLANDO, FL / ACCESS Newswire / September 11, 2026 / RedChip Companies will air interviews with Anixa Biosciences Inc. (NASDAQ:ANIX) and Nexalin Technology Inc.
Anixa Biosciences Q3 EPS $(0.08) Beats $(0.09) Estimate, Sales $0.00, Same YoY
Anixa Biosciences (NASDAQ:ANIX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 11.11 percent. This is a 14.29 percent decrease over losses of $(0.07) per share
Anixa Biosciences Interview Highlighting Breast Cancer Vaccine to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that an interview of Chairman and CEO, Dr. Amit Kumar, and breast cancer vaccine clinical trial patient, Sherie Steinberg, will air on the RedChip Small Stocks, Big Money™ show on Bloomberg TV this Saturday, September 12, at 7:00 PM ET. Bloomberg TV is available in an estimated 73 million homes across the U.S.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-24 | Baskies Arnold M | +5,000 | $2.76 | $13,800 |
| 2026-09-24 | KUMAR AMIT | +7,000 | $2.78 | $19,460 |
| 2026-09-23 | Titterton Lewis H jr | +49,036 | $2.69 | $131,907 |
| 2026-09-10 | Titterton Lewis H jr | +10,000 | $2.73 | $27,300 |
| 2026-09-10 | KUMAR AMIT | +3,000 | $2.75 | $8,250 |
| 2026-09-10 | KUMAR AMIT | +5,000 | $2.76 | $13,800 |
| 2026-07-31 | KUMAR AMIT | +5,000 | $3.47 | $17,350 |
| 2026-07-27 | Baskies Arnold M | -6,000 | - | - |
| 2026-07-27 | Baskies Arnold M | -5,428 | $3.46 | $18,781 |
| 2026-07-27 | Baskies Arnold M | +6,000 | $3.13 | $18,780 |
| 2026-07-27 | KUMAR AMIT | +3,188 | $3.37 | $10,744 |
| 2026-07-27 | KUMAR AMIT | +5,000 | $3.44 | $17,200 |
| 2026-07-24 | KUMAR AMIT | +3,000 | $3.73 | $11,190 |
| 2026-07-20 | KUMAR AMIT | +5,000 | $3.46 | $17,300 |
| 2026-07-20 | Titterton Lewis H jr | +12,000 | $3.47 | $41,640 |
| 2026-07-15 | Titterton Lewis H jr | +2,797 | $3.28 | $9,174 |
| 2026-07-10 | KUMAR AMIT | +5,000 | $3.04 | $15,200 |
| 2026-06-16 | Titterton Lewis H jr | +2,836 | $2.64 | $7,487 |
| 2026-06-12 | KUMAR AMIT | +21,000 | $2.5 | $52,500 |
| 2026-01-28 | Baskies Arnold M | +10,000 | $3.04 | $30,400 |
| 2026-01-05 | Gottschalk Emily | +25,000 | - | - |
| 2026-01-05 | Catelani Michael | +175,000 | - | - |
| 2026-01-05 | Baskies Arnold M | +25,000 | - | - |
| 2026-01-05 | Titterton Lewis H jr | +25,000 | - | - |
| 2026-01-05 | KUMAR AMIT | +350,000 | - | - |
| 2025-12-15 | Titterton Lewis H jr | -16,000 | - | - |
| 2025-12-15 | Titterton Lewis H jr | +16,000 | $2.92 | $46,720 |
| 2025-10-30 | KUMAR AMIT | -200,000 | - | - |
| 2025-10-30 | KUMAR AMIT | -169,439 | $4.06 | $687,922 |
| 2025-10-30 | KUMAR AMIT | +200,000 | $2.92 | $584,000 |